Trials / Completed
CompletedNCT00676312
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects
A Partially-Blinded, Randomized, Placebo and Active Controlled, Ascending Single-Dose Crossover Phase I Study to Explore the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of PTH134 Formulated With Different Concentrations of 5-CNAC in Healthy Postmenopausal Women
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Novartis · Industry
- Sex
- Female
- Age
- 40 Years – 70 Years
- Healthy volunteers
- —
Summary
This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PTH134 |
Timeline
- Start date
- 2008-05-01
- Primary completion
- 2008-08-01
- First posted
- 2008-05-13
- Last updated
- 2008-12-11
Locations
1 site across 1 country: Switzerland
Source: ClinicalTrials.gov record NCT00676312. Inclusion in this directory is not an endorsement.